Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias
Open Access
- 27 September 2006
- journal article
- research article
- Published by Springer Nature in Retrovirology
- Vol. 3 (1) , 64
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is a high-risk type of blood-cell cancer. We describe the improvement of a candidate therapeutic virus for virotherapy of leukemic cells. Virotherapy is based on the exclusive replication of a virus in leukemic cells, leading to the selective removal of these malignant cells. To improve the safety of such a virus, we constructed an HIV-1 variant that replicates exclusively in the presence of the nontoxic effector doxycycline (dox). This was achieved by replacement of the viral TAR-Tat system for transcriptional activation by the Escherichia coli-derived Tet system for inducible gene expression. This HIV-rtTA virus replicates in a strictly dox-dependent manner. In this virus, additional deletions and/or inactivating mutations were introduced in the genes for accessory proteins. These proteins are essential for virus replication in untransformed cells, but dispensable in leukemic T cells. These minimized HIV-rtTA variants contain up to 7 deletions/inactivating mutations (TAR, Tat, vif, vpR, vpU, nef and U3) and replicate efficiently in the leukemic SupT1 T cell line, but do not replicate in normal peripheral blood mononuclear cells. These virus variants are also able to efficiently remove leukemic cells from a mixed culture with untransformed cells. The therapeutic viruses use CD4 and CXCR4 for cell entry and could potentially be used against CXCR4 expressing malignancies such as T-lymphoblastic leukemia/lymphoma, NK leukemia and some myeloid leukemias.Keywords
This publication has 45 references indexed in Scilit:
- A conditionally replicating HIV-based vector that stably expresses an antiviral shRNA against HIV-1 replicationMolecular Therapy, 2006
- Role and Mechanism of Action of the APOBEC3 Family of Antiretroviral Resistance FactorsJournal of Virology, 2006
- Targeted Virus Replication Plus Immunotherapy Eradicates Primary and Distant Pancreatic Tumors in Nude MiceCancer Research, 2005
- Extracellular Nef Protein Targets CD4+T Cells for Apoptosis by Interacting with CXCR4 Surface ReceptorsJournal of Virology, 2004
- Efficient Human Immunodeficiency Virus Replication Requires a Fine-Tuned Level of TranscriptionJournal of Virology, 2002
- Conditional Virus Replication as an Approach to a Safe Live Attenuated Human Immunodeficiency Virus VaccineJournal of NeuroVirology, 2002
- Human Immunodeficiency Virus Type 1-Mediated Syncytium Formation Is Compatible with Adenovirus Replication and Facilitates Efficient Dispersion of Viral Gene Products and De Novo -Synthesized Virus ParticlesHuman Gene Therapy, 2001
- Does the Antitumor Adenovirus ONYX-015/dl1520 Selectively Target Cells Defective in the p53 Pathway?Journal of Virology, 2001
- Strict Control of Human Immunodeficiency Virus Type 1 Replication by a Genetic Switch: Tet for TatJournal of Virology, 2001
- Genomic Structure of an Attenuated Quasi Species of HIV-1 from a Blood Transfusion Donor and RecipientsScience, 1995